On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology.
Also Read: Preclinical-Phase Firm Prime Medicine’s Gene Editing Platform Has Potential: Analyst.
Bristol Myers Squibb will be responsible for developing, manufacturing, and commercializing next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.
Prime Medicine will receive a $55 million ...